---
annotation-target: s41409-022-01759-7.pdf
---


>%%
>```annotation-json
>{"created":"2022-08-30T03:35:38.863Z","updated":"2022-08-30T03:35:38.863Z","document":{"title":"Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT","link":[{"href":"urn:x-pdf:319bb773bac51a5ef3679675f264a1b9"},{"href":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf"}],"documentFingerprint":"319bb773bac51a5ef3679675f264a1b9"},"uri":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","selector":[{"type":"TextPositionSelector","start":38,"end":75},{"type":"TextQuoteSelector","exact":"CPSS cytogenetic risk classification ","prefix":"PONDENCEOPENPrognostic value of ","suffix":"inpatients with CMML after allog"}]}]}
>```
>%%
>*%%PREFIX%%PONDENCEOPENPrognostic value of%%HIGHLIGHT%% ==CPSS cytogenetic risk classification== %%POSTFIX%%inpatients with CMML after allog*
>%%LINK%%[[#^h87czsn0i5|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^h87czsn0i5


>%%
>```annotation-json
>{"created":"2022-08-30T03:35:59.345Z","updated":"2022-08-30T03:35:59.345Z","document":{"title":"Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT","link":[{"href":"urn:x-pdf:319bb773bac51a5ef3679675f264a1b9"},{"href":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf"}],"documentFingerprint":"319bb773bac51a5ef3679675f264a1b9"},"uri":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","selector":[{"type":"TextPositionSelector","start":339,"end":556},{"type":"TextQuoteSelector","exact":"The only curative treatment approach for patients with chronicmyelomonocytic leukemia (CMML) is allogeneic hematopoieticcell transplantation (allo-HCT), but disease relapse after transplan-tation is a major concern [1","prefix":"s41409-022-01759-7TO THE EDITOR:","suffix":"]. Predictors for disease outcom"}]}]}
>```
>%%
>*%%PREFIX%%s41409-022-01759-7TO THE EDITOR:%%HIGHLIGHT%% ==The only curative treatment approach for patients with chronicmyelomonocytic leukemia (CMML) is allogeneic hematopoieticcell transplantation (allo-HCT), but disease relapse after transplan-tation is a major concern [1== %%POSTFIX%%]. Predictors for disease outcom*
>%%LINK%%[[#^r6t4fbq8q48|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^r6t4fbq8q48


>%%
>```annotation-json
>{"created":"2022-08-30T03:36:29.677Z","updated":"2022-08-30T03:36:29.677Z","document":{"title":"Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT","link":[{"href":"urn:x-pdf:319bb773bac51a5ef3679675f264a1b9"},{"href":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf"}],"documentFingerprint":"319bb773bac51a5ef3679675f264a1b9"},"uri":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","selector":[{"type":"TextPositionSelector","start":971,"end":1552},{"type":"TextQuoteSelector","exact":" patients can be categorized into three risk groups(high risk: trisomy 8, chromosome 7 abnormalities, or complexkaryotype; low risk: normal karyotype and -Y; intermediate risk: allother chromosomal abnormalities) [8]. There is evidence, thatadverse cytogenetics are also a risk factor for worse outcome afterallo-HCT [9]. However, cytogenetic information according to CPSSwas not evaluated in the setting of allo-HCT to date. Therefore, theaim of this large multicentric, international study was toretrospectively determine the impact of CPSS-cytogenetic onoutcome after allo-HSCT.","prefix":" prognostic scoringsystem (CPSS)","suffix":"Adult patients (age > =18years) "}]}]}
>```
>%%
>*%%PREFIX%%prognostic scoringsystem (CPSS)%%HIGHLIGHT%% ==patients can be categorized into three risk groups(high risk: trisomy 8, chromosome 7 abnormalities, or complexkaryotype; low risk: normal karyotype and -Y; intermediate risk: allother chromosomal abnormalities) [8]. There is evidence, thatadverse cytogenetics are also a risk factor for worse outcome afterallo-HCT [9]. However, cytogenetic information according to CPSSwas not evaluated in the setting of allo-HCT to date. Therefore, theaim of this large multicentric, international study was toretrospectively determine the impact of CPSS-cytogenetic onoutcome after allo-HSCT.== %%POSTFIX%%Adult patients (age > =18years)*
>%%LINK%%[[#^dzvswqyzsg|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^dzvswqyzsg


>%%
>```annotation-json
>{"created":"2022-08-30T03:39:36.859Z","updated":"2022-08-30T03:39:36.859Z","document":{"title":"Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT","link":[{"href":"urn:x-pdf:319bb773bac51a5ef3679675f264a1b9"},{"href":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf"}],"documentFingerprint":"319bb773bac51a5ef3679675f264a1b9"},"uri":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220808/s41409-022-01759-7.pdf","selector":[{"type":"TextPositionSelector","start":8805,"end":9381},{"type":"TextQuoteSelector","exact":"Our results show that CPSS cytogenetics is a strong predictor ofrelapse and overall survival after allo-HCT. Adverse cytogeneticalterations lead to a disease biology which is more likely to beresistant to an allograft. This observation has been made in avariety of myeloid malignant diseases, such as MDS and AML [11].Currently, molecular diagnostics are becoming more and morestandard in patients with CMML. We were not able to include suchinformation into this retrospective study. It might be that evenmore distinct risk-groups can be identified using that diagnostictool [","prefix":"as associated withsurvival [10].","suffix":"5].In this international, multic"}]}]}
>```
>%%
>*%%PREFIX%%as associated withsurvival [10].%%HIGHLIGHT%% ==Our results show that CPSS cytogenetics is a strong predictor ofrelapse and overall survival after allo-HCT. Adverse cytogeneticalterations lead to a disease biology which is more likely to beresistant to an allograft. This observation has been made in avariety of myeloid malignant diseases, such as MDS and AML [11].Currently, molecular diagnostics are becoming more and morestandard in patients with CMML. We were not able to include suchinformation into this retrospective study. It might be that evenmore distinct risk-groups can be identified using that diagnostictool [== %%POSTFIX%%5].In this international, multic*
>%%LINK%%[[#^elpj74pohpo|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^elpj74pohpo
